Literature DB >> 31599831

Extracorporeal Therapies for Amniotic Fluid Embolism.

Julien Viau-Lapointe1, Niall Filewod.   

Abstract

BACKGROUND: Amniotic fluid embolism (AFE) is a catastrophic disease with significant mortality. Because the cardiopulmonary dysfunction associated with AFE is self-limited, the disease could be well suited to the use of extracorporeal therapies. CASE: A woman progressed into cardiac arrest immediately after an elective cesarean delivery. Owing to severe hypoxemia and hypotension, AFE was suspected and peripheral venoarterial extracorporeal membrane oxygenation was quickly initiated. Subsequent evolution was complicated by intrabdominal bleeding, which required massive transfusion and multiple surgeries. The patient recovered well, with a healthy newborn. We have identified 19 similar cases in the literature and present their outcomes as a series.
CONCLUSION: Extracorporeal therapies can support severely ill women affected by AFE and could be considered even in the presence of disseminated intravascular coagulation and bleeding.

Entities:  

Mesh:

Year:  2019        PMID: 31599831     DOI: 10.1097/AOG.0000000000003513

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  3 in total

1.  Extracorporeal Membrane Oxygenation for Amniotic Fluid Embolism-Induced Cardiac Arrest in the First Trimester of Pregnancy: A Case Report.

Authors:  Christina Creel-Bulos; Brian Hassani; Michael J Stentz; Gaurav Budhrani; Mani A Daneshmand; Craig S Jabaley; Robert F Groff
Journal:  Crit Care Explor       Date:  2020-07-16

2.  Rotational Thromboelastometry-Guided Venoarterial Extracorporeal Membrane Oxygenation in the Treatment of Amniotic Fluid Embolism.

Authors:  Jillian K Wothe; Elizabeth Elfstrand; Michael R Mooney; Donald D Wothe
Journal:  Case Rep Obstet Gynecol       Date:  2022-05-18

3.  [Special pathologies of pregnant patients in intensive care medicine].

Authors:  Sophie Neuhaus; Christopher Neuhaus; Markus A Weigand; Dorothee Bremerich
Journal:  Anaesthesist       Date:  2021-04-13       Impact factor: 1.041

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.